Biora Therapeutics (BIOR) Competitors $3.35 -0.08 (-2.33%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BIOR vs. ADAG, ACET, BDSX, CUE, STTK, ALMS, ORIC, NUVB, SLN, and AURAShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Adagene (ADAG), Adicet Bio (ACET), Biodesix (BDSX), Cue Biopharma (CUE), Shattuck Labs (STTK), Alumis (ALMS), ORIC Pharmaceuticals (ORIC), Nuvation Bio (NUVB), Silence Therapeutics (SLN), and Aura Biosciences (AURA). These companies are all part of the "medical" sector. Biora Therapeutics vs. Adagene Adicet Bio Biodesix Cue Biopharma Shattuck Labs Alumis ORIC Pharmaceuticals Nuvation Bio Silence Therapeutics Aura Biosciences Adagene (NASDAQ:ADAG) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do analysts recommend ADAG or BIOR? Adagene presently has a consensus price target of $5.00, indicating a potential upside of 66.67%. Biora Therapeutics has a consensus price target of $150.00, indicating a potential upside of 4,404.50%. Given Biora Therapeutics' higher possible upside, analysts plainly believe Biora Therapeutics is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in ADAG or BIOR? 9.5% of Adagene shares are owned by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 51.1% of Biora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, ADAG or BIOR? Adagene has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Is ADAG or BIOR more profitable? Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Biora Therapeutics N/A N/A -228.89% Does the media refer more to ADAG or BIOR? In the previous week, Biora Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Biora Therapeutics and 3 mentions for Adagene. Adagene's average media sentiment score of 0.97 beat Biora Therapeutics' score of 0.44 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, ADAG or BIOR? Adagene has higher revenue and earnings than Biora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$18.11M7.33-$18.95MN/AN/ABiora TherapeuticsN/AN/A-$124.11M-$56.90-0.06 Does the MarketBeat Community believe in ADAG or BIOR? Adagene received 14 more outperform votes than Biora Therapeutics when rated by MarketBeat users. Likewise, 80.77% of users gave Adagene an outperform vote while only 77.78% of users gave Biora Therapeutics an outperform vote. CompanyUnderperformOutperformAdageneOutperform Votes2180.77% Underperform Votes519.23%Biora TherapeuticsOutperform Votes777.78% Underperform Votes222.22% SummaryAdagene beats Biora Therapeutics on 6 of the 11 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.25M$7.41B$5.48B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-0.0612.34128.5016.14Price / SalesN/A400.631,495.8497.42Price / CashN/A47.4339.6734.18Price / Book-0.095.604.765.07Net Income-$124.11M$153.56M$119.00M$225.46M7 Day Performance-14.62%0.13%0.79%0.54%1 Month Performance-33.40%15.20%5.64%3.75%1 Year Performance-83.10%41.11%36.71%29.48% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora Therapeutics3.3068 of 5 stars$3.35-2.3%$150.00+4,378.4%-83.3%$12.61MN/A-0.06120News CoverageADAGAdagene3.2775 of 5 stars$3.01+3.8%$5.00+66.1%+127.6%$132.91M$815,746.000.00260Gap UpACETAdicet Bio2.5266 of 5 stars$1.40-1.4%$7.50+435.7%-3.8%$115.04M$24.99M-0.5590Positive NewsBDSXBiodesix3.6193 of 5 stars$1.64+0.6%$3.06+86.6%-6.5%$188.09M$60.90M-3.57220Earnings ReportNews CoverageCUECue Biopharma4.6538 of 5 stars$1.48-5.1%$5.00+237.8%-24.8%$71.99M$8.30M-1.5360Positive NewsGap UpHigh Trading VolumeSTTKShattuck Labs3.5867 of 5 stars$1.31+2.3%$8.67+561.6%-22.4%$62.29M$4.12M-0.71100Gap DownHigh Trading VolumeALMSAlumisN/A$11.90-0.6%$28.00+135.3%N/A$554.89MN/A0.00N/AAnalyst ForecastNews CoverageORICORIC Pharmaceuticals4.2027 of 5 stars$8.15-3.4%$18.00+120.9%+43.2%$549.49MN/A-4.6680Upcoming EarningsAnalyst ForecastNews CoverageNUVBNuvation Bio3.8148 of 5 stars$2.21-3.9%$6.40+189.6%+98.3%$546.25M$1.44M-1.0560Upcoming EarningsSLNSilence Therapeutics2.7417 of 5 stars$18.08+0.6%$57.20+216.4%+104.2%$541.10M$17.90M-14.82100AURAAura Biosciences3.8257 of 5 stars$10.92-2.8%$23.00+110.6%+13.2%$541.01MN/A-6.1050Short Interest ↓ Related Companies and Tools Related Companies Adagene Competitors Adicet Bio Competitors Biodesix Competitors Cue Biopharma Competitors Shattuck Labs Competitors Alumis Competitors ORIC Pharmaceuticals Competitors Nuvation Bio Competitors Silence Therapeutics Competitors Aura Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIOR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIOR Stock Alerts